Research programme: ketone body neuroprotectants - KetoCytonyx
Alternative Names: KTX 02; KTX 03Latest Information Update: 21 Aug 2019
At a glance
- Originator BTG
- Class Ketone bodies
- Mechanism of Action Mitochondrial membrane transport protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinson's disease; Stroke
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 07 May 2007 No development reported - Preclinical for Parkinson's disease in United Kingdom (unspecified route)
- 07 May 2007 No development reported - Preclinical for Stroke in United Kingdom (unspecified route)